114 Preclinical development of a novel iPSC-derived CAR-MICA/B NK cell immunotherapy to overcome solid tumor escape from NKG2D-mediated mechanisms of recognition and killing

• Tom Lee,
• John Goulding,
• Mochtar Pribadi,
• Robert Blum,
• Wen-I Yeh,
• Yijia Pan,
• Svetlana Gaidarova,
• Chia-Wei Chang,
• Hui-Yi Chu,
• Ellen Liu,
• Shohreh Sikaroodi,
• Lucas Ferrari de Andrade,
• Lauren Fong,
• Janel Huffman,
• Ryan Bjordahl,
• Kai Wucherpfennig,
• Bahram Valamehr

Affiliations

Tom Lee

1Fate Therapeutics, San Diego, CA, USA

John Goulding

1Fate Therapeutics, San Diego, CA, USA

Mochtar Pribadi

1Fate Therapeutics, San Diego, CA, USA

Robert Blum

1Fate Therapeutics, San Diego, CA, USA

Wen-I Yeh

1Fate Therapeutics, San Diego, CA, USA

Yijia Pan

1Fate Therapeutics, San Diego, CA, USA

Svetlana Gaidarova

1Fate Therapeutics, San Diego, CA, USA

Chia-Wei Chang

1Fate Therapeutics, San Diego, CA, USA

Hui-Yi Chu

1Fate Therapeutics, San Diego, CA, USA

Ellen Liu

1Fate Therapeutics, San Diego, CA, USA

Shohreh Sikaroodi

1Fate Therapeutics, San Diego, CA, USA

Lucas Ferrari de Andrade

2Icahn School of Medicine at Mount Sinai, New York, NY, USA

Lauren Fong

1Fate Therapeutics, San Diego, CA, USA

Janel Huffman

1Fate Therapeutics, San Diego, CA, USA

Ryan Bjordahl

1Fate Therapeutics, San Diego, CA, USA

Kai Wucherpfennig

3Dana-Farber Cancer Institute, Boston, MA, USA

Bahram Valamehr

1Fate Therapeutics, San Diego, CA, USA